Literature DB >> 17375350

Nesiritide for the treatment of pulmonary hypertension and cor pulmonale in an infant.

E W Reynolds1, E T Conely, M Vranicar.   

Abstract

Nesiritide is a synthetic form of B-type natriuretic peptide. It is approved for the treatment of acute exacerbations of congestive heart failure in hospitalized adult patients. It is currently under investigation for use in other settings and other patient populations. This article describes administration of nesiritide to an infant patient with severe pulmonary hypertension and cor pulmonale. No adverse reactions occurred during administration of the drug. Specifically, there was no hypertension, vomiting, arrhythmia, or changes in renal function. No changes in renal function occurred in the months subsequent to treatment. This case report illustrates that nesiritide can be safely administered to critically ill infants with pulmonary hypertension and cor pulmonale. Our patient experienced a decrease in pulmonary pressure and improved clinical condition during and after the infusion. However, further study is required to fully evaluate the safety and efficacy of nesiritide for these patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17375350     DOI: 10.1007/s00246-006-0064-6

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  19 in total

1.  A 1-year follow-up of low birth weight infants with and without bronchopulmonary dysplasia: health, growth, clinical lung disease, cardiovascular and neurological sequelae.

Authors:  O K Tammela; M E Koivisto
Journal:  Early Hum Dev       Date:  1992-09       Impact factor: 2.079

2.  Nesiritide in infants and children with congestive heart failure.

Authors:  William T Mahle; Angel R Cuadrado; Paul M Kirshbom; Kirk R Kanter; Janet M Simsic
Journal:  Pediatr Crit Care Med       Date:  2005-09       Impact factor: 3.624

3.  Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials.

Authors:  Jonathan D Sackner-Bernstein; Marcin Kowalski; Marshal Fox; Keith Aaronson
Journal:  JAMA       Date:  2005-04-20       Impact factor: 56.272

4.  Nesiritide use in pediatric patients with congestive heart failure.

Authors:  Brian Feingold; Yuk M Law
Journal:  J Heart Lung Transplant       Date:  2004-12       Impact factor: 10.247

5.  Brain-type natriuretic peptide in the diagnosis and management of persistent pulmonary hypertension of the newborn.

Authors:  Eric W Reynolds; Jeff G Ellington; Mark Vranicar; Henrietta S Bada
Journal:  Pediatrics       Date:  2004-11       Impact factor: 7.124

6.  The use of a bedside assay for plasma B-type natriuretic peptide as a biomarker in the management of patent ductus arteriosus in premature neonates.

Authors:  Patrick A Flynn; Ralph L da Graca; Peter A M Auld; Mirjana Nesin; Charles S Kleinman
Journal:  J Pediatr       Date:  2005-07       Impact factor: 4.406

7.  Atrial natriuretic peptide and brain natriuretic peptide in cor pulmonale. Hemodynamic and endocrine effects.

Authors:  R I Cargill; B J Lipworth
Journal:  Chest       Date:  1996-11       Impact factor: 9.410

Review 8.  B-type natriuretic Peptide and the right heart.

Authors:  Lok Bin Yap
Journal:  Heart Fail Rev       Date:  2004-04       Impact factor: 4.214

Review 9.  Natriuretic peptides, respiratory disease, and the right heart.

Authors:  Lok Bin Yap; Dev Mukerjee; Peter M Timms; Houman Ashrafian; John Gerard Coghlan
Journal:  Chest       Date:  2004-10       Impact factor: 9.410

10.  Preliminary experience with nesiritide in the pediatric population.

Authors:  Julie Marshall; John W Berkenbosch; Pierantonio Russo; Joseph D Tobias
Journal:  J Intensive Care Med       Date:  2004 May-Jun       Impact factor: 3.510

View more
  2 in total

Review 1.  Management of hypoxemic respiratory failure and pulmonary hypertension in preterm infants.

Authors:  N Ambalavanan; J L Aschner
Journal:  J Perinatol       Date:  2016-06       Impact factor: 2.521

2.  Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent.

Authors:  Brian Casserly; James R Klinger
Journal:  Drug Des Devel Ther       Date:  2009-12-29       Impact factor: 4.162

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.